A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
MoMMent
A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma
2 other identifiers
observational
300
11 countries
87
Brief Summary
The purpose of this study is to assess in real-life clinical practice, over a 24-month period, the effectiveness and safety and patient-reported outcomes (PROs) associated with standard of care (SOC) antimyeloma treatments in participants with previously treated relapsed and/or refractory multiple myeloma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2021
Longer than P75 for all trials
87 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 18, 2021
CompletedFirst Submitted
Initial submission to the registry
December 15, 2021
CompletedFirst Posted
Study publicly available on registry
December 16, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 31, 2028
April 13, 2026
April 1, 2026
6.5 years
December 15, 2021
April 9, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Overall Response Rate (ORR)
Overall Response Rate is defined as the percentage of participants who achieve a partial response (PR) or better response according to the International Myeloma Working Group (IMWG) response criteria, as assessed by Response Review Committee (RRC).
Up to 52 months
Secondary Outcomes (20)
Very Good Partial Response (VGPR) Rate
Up to 52 months
Complete Response (CR) Rate
Up to 52 months
Stringent Complete Response (sCR) Rate
Up to 52 months
Minimal Residual Disease (MRD) Negative Rate
Up to 52 months
Clinical Benefit Rate (CBR)
Up to 52 months
- +15 more secondary outcomes
Study Arms (1)
Participants with Relapsed/Refractory Multiple Myeloma
Participants with relapsed/refractory multiple myeloma (RRMM) receiving antimyeloma treatment as standard of care (SOC) under routine clinical practice will be observed. The primary data source will be medical records of each participant.
Interventions
There is no interventional treatment component for participants with RRMM in this study.
Eligibility Criteria
The study population consists of participants with previously treated multiple myeloma, having received standard of care (SOC) antimyeloma treatments during local clinical practices.
You may qualify if:
- For Period 1 and 2: Have a documented diagnosis of multiple myeloma according to International myeloma working group (IMWG) diagnostic criteria. For Period 3: Start of talquetamab for the treatment of a documented diagnosis of relapsed and/or refractory multiple myeloma (RRMM) according to IMWG diagnostic criteria and the approved indication. The decision to start talquetamab must be made independently of the decision to participate in the study, with the start of treatment occurring up to 28 days following the start of screening or having occurred up to 21 days before the informed consent form (ICF) date
- For Period 1 and 2: Have an Eastern Cooperative Oncology Group (ECOG) Performance Status grade of 0 or 1. For Period 3: Have ECOG performance status of 0,1 or 2
- For Period 1,2 and 3: Must not be pregnant or must not plan to become pregnant within the study period
- For Period 1,2 and 3: Participants must sign an ICF indicating that he or she understands the purpose and observational nature of the study and is willing to participate. Consent is to be obtained prior to the initiation of any study-related data collection
- For Period 1 and 2: Received at least 3 prior lines of therapy (induction with or without hematopoietic stem cell transplant and with or without maintenance therapy is considered a single regimen). Undergone at least 1 complete cycle of treatment for each line of therapy, unless progressive disease (PD) was the best response to the line of therapy
- For Period 1 and 2: Must have documented evidence of progressive disease based on participating physician's determination of response by the IMWG response criteria on or after the last regimen. Participants with documented evidence of progressive disease within the previous 6 months and who are refractory or non-responsive to their most recent line of treatment afterwards are also eligible
- For Period 1 and 2: Measurable disease at screening as defined by any of the following: Serum monoclonal paraprotein (M-protein) level 1.0 g/dL or urine M-protein level 200 mg/24 hours; or Light chain multiple myeloma without measurable disease in the serum or the urine: Serum immunoglobulin free light chain 10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio
- Period 1: Received as part of previous therapy a PI, an IMiD, and an anti-CD38 antibody (prior exposure can be from different monotherapy or combination regimens)
- Period 2: Received as part of previous therapy a PI, an IMiD, an anti-CD38 antibody, and BCMA-targeted therapy (prior exposure can be from different monotherapy or combination regimens)
- For period 3: At least one of the following prior to the start of talquetamab: a. Measurable disease at screening as defined by any of the following: Serum monoclonal paraprotein (M-protein) level greater than or equal to (\>=) 0.5 grams per deciliter (g/dL) or urine M-protein level \>= 200 milligram (mg) /24 hours; or b. serum immunoglobulin free light chain \>= 10 milligrams per deciliter (mg/dL) and abnormal ratio of involved and uninvolved free light chains or c. presence of bone lesions or plasmacytomas (\>=1 lesion has 2 diameters \>= 1 centimeter \[cm\])
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (87)
LKH Leoben
Leoben, 8700, Austria
Krankenhaus der barmherzigen Schwestern
Vienna, 1060, Austria
UZ Antwerpen
Edegem, 2650, Belgium
Ziekenhuis Oost-Limburg
Genk, 3600, Belgium
UZ Leuven
Leuven, 3000, Belgium
Chu Helora Hospital De Mons Site Kennedy
Mons, 7000, Belgium
Vitaz
Sint-Niklaas, 9100, Belgium
Ucl de Mont-Godinne
Yvoir, 5530, Belgium
CHRU de Lille Hopital Claude Huriez
Lille, 59037, France
CHU de Montpellier Hopital Saint Eloi
Montpellier, 34295, France
CHU de Nantes hotel Dieu
Nantes, 44093, France
Centre hospitalier Lyon-Sud
Pierre-Bénite, 69495, France
Pôle IUC Oncopole CHU
Toulouse, 31059, France
Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin
Berin, 12203, Germany
Universitaetsklinikum Koeln
Cologne, 50397, Germany
Universitatsklinikum Carl Gustvav Carus Dresden an der Technischen Universitat Dresden
Dresden, 01307, Germany
Universitätsklinik Hamburg-Eppendorf - Orthopädische Universitätsklinik und Poliklinik
Hamburg, 20251, Germany
St. Barbara-Klinik Hamm GmbH
Hamm, 59073, Germany
Universitaetsklinikum Heidelberg
Heidelberg, 69120, Germany
Staedtisches Klinikum Karlsruhe gGmbH
Karlsruhe, Germany
MVZ Mitte-Onkologische Schwerpunktpraxis
Leipzig, 04103, Germany
Universitaetsklinikum Leipzig
Leipzig, 4103, Germany
Klinikum der Eberhard Karls Universitaet Abt fur innere Med II Haematologie Onkologie Germany
Tübingen, 72076, Germany
Universitatsklinikum Wurzburg
Würzburg, 97080, Germany
Heinrich-Braun-Klinikum gGmbH
Zwickau, 08060, Germany
University Hospital of Alexandroupolis
Alexandroupoli, 68100, Greece
Henry Dunant Hospital Center
Athens, 115 26, Greece
Laiko General Hospital Of Athens 1
Athens, 115 27, Greece
Laiko General Hospital of Athens 2
Athens, 115 27, Greece
Alexandra Hospital
Athens, 115 28, Greece
Metaxa Cancer Center Hospital Of Piraeus
Piraeus, 18537, Greece
General University Hospital of Patras
Rio, 265 04, Greece
Anticancer Hospital of Thessaloniki Theageneio
Thessaloniki, 546 39, Greece
Ahepa University General Hospital of Thessaloniki
Thessaloniki, 54636, Greece
Oncologia Medica - Irccs - Istituto Tumori Giovanni Paolo II
Bari, 70124, Italy
U.O. Ematologia Istituto Tumori Giovanni Paolo II
Bari, 70124, Italy
Istituto di Ematologia Seràgnoli azienda ospedaliera univeristaria Policlinico S.Orsola-Malpighi
Bologna, 40138, Italy
Policlinico di Catania
Catania, 95128, Italy
Ospedale Civile di Civitanova Marche
Civitanova Marche, 62012, Italy
IRCCS Azienda Ospedaliera San Martino - IST
Genova, 16132, Italy
Ospedale Policlinico San Martino IRCCS
Genova, 16132, Italy
Ospedale Vito Fazzi
Lecce, 73100, Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Meldola, 47014, Italy
Universita degli Studi di Padova Azienda Ospedaliera di Pa
Padova, 35128, Italy
Ospedale Villa Sofia-Cervello
Palermo, 90146, Italy
Fondazione IRCCS Policlinico San Matteo
Pavia, 27100, Italy
Presidio Ospedaliero Pescara
Pescara, 65124, Italy
Grande Ospedale Metropolitano 'Bianchi-Melacrino-Morelli' Reggio Calabria
Reggio Calabria, 89124, Italy
Università di Roma La Sapienza
Roma, 00161, Italy
Fondazione Policlinico Universitario A Gemelli IRCCS
Roma, 00168, Italy
Campus Bio Medico di Roma
Roma, 128, Italy
Casa Sollievo Della Sofferenza IRCCS
San Giovanni Rotondo, 71013, Italy
IRCCS Ospedale Casa Sollievo della Sofferenza
San Giovanni Rotondo, 71013, Italy
Ospedale Cardinale G. Panico
Tricase, 73039, Italy
Azienda Ulss 8 Berica- Ospedale Di Vicenza
Vicenza, 36100, Italy
VU Medisch Centrum
Amsterdam, 1081 HV, Netherlands
UMCG
Groningen, 9713 GZ, Netherlands
Ulstmad - Hosp. Chaves
Chaves, 5400 482, Portugal
Uls Coimbra - Hosp. Univ. Coimbra
Coimbra, 3004 561, Portugal
Uls Sao Joao - Hosp. Sao Joao
Porto, 4200 319, Portugal
Inst. Cat. Doncologia-H Duran I Reynals
Barcelona, 08908, Spain
Hosp. de Cabuenes
Gijón, 33394, Spain
Hosp. Univ. Virgen de Las Nieves
Granada, 18014, Spain
Hosp. de Jerez de La Frontera
Jerez de la Frontera, 11407, Spain
Hosp. de Leon
León, 24008, Spain
Hosp. Univ. Ramon Y Cajal
Madrid, 28034, Spain
Hosp. Univ. 12 de Octubre
Madrid, 28041, Spain
Hosp. Univ. Son Espases
Palma, 7120, Spain
Clinica Univ. de Navarra
Pamplona, 31008, Spain
Hosp Clinico Univ de Salamanca
Salamanca, 37007, Spain
Hosp. Univ. Marques de Valdecilla
Santander, 39008, Spain
Hosp. Clinico Univ. de Santiago
Santiago de Compostela, 15706, Spain
Hosp. Clinico Univ. de Valencia
Valencia, 46010, Spain
Hosp. Univ. Dr. Peset
Valencia, 46017, Spain
Hosp. Clinico Univ. de Valladolid
Valladolid, 47003, Spain
Hosp. Univ. Miguel Servet
Zaragoza, 50009, Spain
Kantonsspital Graubunden
Chur, 7000, Switzerland
Kantonsspital Winterthur, Medizinische Onkologie
Winterthur, 8400, Switzerland
Hirslanden Klinik Hirslanden
Zurich, 8032, Switzerland
Universitatsspital Zurich
Zurich, 8091, Switzerland
Southmead Hospital
Bristol, BS10 5NB, United Kingdom
University College Hospital
London, NW1 2PG, United Kingdom
Kings College Hospital
London, SE5 9RS, United Kingdom
St Georges Hospital
London, SW17 OQT, United Kingdom
Maidstone Hospital
Maidstone, ME16 9QQ, United Kingdom
Nottingham University Hospitals NHS Trust
Nottingham, NG5 1PB, United Kingdom
The Royal Marsden NHS Trust Sutton
Surrey, SM2 5PT, United Kingdom
Related Publications (3)
Einsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L, Perrot A, Goldschmidt H, van de Donk NWCJ, Ocio EM, Martinez Lopez J, Rodriguez-Otero P, Dytfeld D, Jakubowiak A, Schinke C, Besemer B, Anguille S, Manier S, Rasche L, Teipel R, Scheid C, Pawlyn C, Cavo M, Diels J, Ghilotti F, Lau BW, Renaud T, Orel O, Ong F, Ramos DF, Ammann E, Parekh T, Albrecht C, Weisel K, Mateos MV. Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent. Adv Ther. 2026 Jan;43(1):333-355. doi: 10.1007/s12325-025-03409-y. Epub 2025 Nov 28.
PMID: 41313549DERIVEDEinsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L, Perrot A, Goldschmidt H, van de Donk NWCJ, Ocio EM, Martinez-Lopez J, Rodriguez-Otero P, Dytfeld D, Diels J, Strulev V, Haddad I, Renaud T, Ammann E, Cabrieto J, Perualila N, Gan R, Zhang Y, Parekh T, Albrecht C, Weisel K, Mateos MV. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma. Adv Ther. 2024 Apr;41(4):1576-1593. doi: 10.1007/s12325-024-02797-x. Epub 2024 Feb 24.
PMID: 38402374DERIVEDMoreau P, Mateos MV, Gonzalez Garcia ME, Einsele H, De Stefano V, Karlin L, Lindsey-Hill J, Besemer B, Vincent L, Kirkpatrick S, Delforge M, Perrot A, van de Donk NWCJ, Pawlyn C, Manier S, Leleu X, Martinez-Lopez J, Ghilotti F, Diels J, Morano R, Albrecht C, Strulev V, Haddad I, Pei L, Kobos R, Smit J, Slavcev M, Marshall A, Weisel K. Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma. Adv Ther. 2024 Feb;41(2):696-715. doi: 10.1007/s12325-023-02738-0. Epub 2023 Dec 19.
PMID: 38110653DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Janssen Pharmaceutica N.V., Belgium Clinical Trial
Janssen Pharmaceutica N.V., Belgium
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 15, 2021
First Posted
December 16, 2021
Study Start
November 18, 2021
Primary Completion (Estimated)
April 30, 2028
Study Completion (Estimated)
July 31, 2028
Last Updated
April 13, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will share
The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.